In contrast, the meta-analysis done by Amjad et al.49 showed no statistically significant difference in fibrosis regression utilizing FIB-4 score (SMD = − 0.12, 95% CI: − 0.41 to 0.1, p = 0.994, I2 = 0%) and hepatic steatosis by using MRI-PDFF (SMD = − 0.31, 95% CI: –0.68 to 0.07, p = 0.502, I2 = 0%) between SGLT-2 inhibitors versus controls. This evidence concerns the gene SLC5A2 and fatty liver disease.